CD23
Dotaz
Zobrazit nápovědu
Závěrečná zpráva o řešení grantu Interní grantové agentury MZ ČR
Přeruš. str. : il. ; 32 cm
Distribuce a intenzita exprese CD23,CD11b a CD11c na buňkách revmatoidní synoviální tkáně.In vitro inhibice CD23 molekuly a jejich ligandů v tkáňových kulturách revmatoidních synoviálních buněk pomocí monoklonálních protilátek.
- MeSH
- chemokiny analýza imunologie MeSH
- monoklonální protilátky terapeutické užití MeSH
- receptory chemokinů MeSH
- revmatoidní artritida terapie patofyziologie imunologie MeSH
- Th1 buňky MeSH
- Th2 buňky MeSH
- Konspekt
- Patologie. Klinická medicína
- NLK Obory
- revmatologie
- alergologie a imunologie
- NLK Publikační typ
- závěrečné zprávy o řešení grantu IGA MZ ČR
The aim of the study here was to evaluate the association between expression of CD23 molecule on B-lymphocytes and the level of specific IgE to molecular components of birch, Bermuda grass, hazel pollen, timothy, and rye grass in atopic dermatitis (AD) patients (with and without dupilumab therapy). A total of 46 patients suffering from AD were included: 26 without dupilumab treatment and 20 with dupilumab treatment. Serum levels of specific IgE were measured by the components resolved diagnostic assay ALEX2 Allergy Xplorer, the expression of CD23 molecule on B-lymphocytes was evaluated with flow cytometry. For the statistical analysis, the Spearman's rank correlation coefficient was used. In patients treated with dupilumab, the higher association was observed between the expression of CD23 on B-lymphocytes and specific IgE to molecular components Bet v 1, Cor a 1.0103, Cor a 1.0401, and Phl p 1. This study demonstrated that the relationship between CD23 expression on B-lymphocytes and specific IgE to pollen molecular components varies depending on whether the patient was treated with dupilumab and the type of molecular component involved.
- MeSH
- alergeny imunologie MeSH
- atopická dermatitida * imunologie farmakoterapie MeSH
- B-lymfocyty * imunologie MeSH
- dospělí MeSH
- humanizované monoklonální protilátky * terapeutické užití MeSH
- imunoglobulin E * krev imunologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- pyl * imunologie MeSH
- receptory IgE * metabolismus imunologie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- MeSH
- alergie diagnóza etiologie MeSH
- B-lymfocyty krev MeSH
- imunoglobuliny krev MeSH
- receptory IgE krev MeSH
- Publikační typ
- kongresy MeSH
BACKGROUND: Eosinophils, basophils, and the molecule CD23 on B cells are involved in the pathophysiology of atopic dermatitis (AD). The molecule CD23 is involved in the regulation of IgE synthesis and is expressed by activated B cells. The molecule CD16 is used to assess the activation of eosinophils and CD203 of basophils. The association between the count of eosinophils, basophils, CD16+ eosinophils, CD203+ basophils and the expression of the activation marker CD23 on B cells in patients with AD (with and without dupilumab therapy) is not described. OBJECTIVE: The aim of this pilot study is to evaluate the association between the blood count of eosinophils, basophils, relative CD16+ eosinophils, relative CD203+ basophils, and the expression of molecule CD23 on B cells and on their subsets (total, memory, naive, switched, non-switched) in patients suffering from AD (with and without dupilumab therapy) and in control group. METHODS: A total of 45 patients suffering from AD were examined; 32 patients without dupilumab treatment (10 men, 22 women, average age 35 years), 13 patients with dupilumab treatment (7 men, 6 women, average age 43.4 years), and 30 subjects as a control group (10 men, 20 women, average age 44.7 years). Immunophenotype was examined by flow cytometry in which monoclonal antibodies with fluorescent molecules were used. For statistical analysis we used non-parametric Kruskal-Wallis one-factor analysis of variance with post hoc by Dunn's test with Bonferroni modification and the Spearman's rank correlation coefficient; for coefficients higher than 0.41, we report R2 (percent of variation explained). RESULTS: The absolute count of eosinophils was significantly higher in patients with AD (with and without dupilumab) in comparison to healthy subjects. The difference in the relative count of CD16+ eosinophils in patients with AD (with and without dupilumab therapy) compared with control is not statistically significant. In patients with dupilumab therapy the significantly lower count of relative CD203+ basophils was confirmed compared with control. The higher association between the count of eosinophils (absolute and relative) and the expression of CD23 marker on B cells was confirmed in patients with dupilumab therapy; in contrast, this association was low in patients with AD without dupilumab therapy and in healthy subjects. CONCLUSION: The higher association between the count of eosinophils (absolute and relative) and the expression of CD23 marker on B cells was confirmed in patients with AD under dupilumab therapy. It suggests that IL-4 production by eosinophils may play a role in B lymphocyte activation. The significantly lower count of CD203+ basophils has been demonstrated in patients with dupilumab therapy. This reduction of CD203+ basophil count may contribute to the therapeutic effects of dupilumab by reducing the inflammatory response and allergic reactions in patients with AD.
- Publikační typ
- časopisecké články MeSH
BACKGROUND: There are a lot of studies that describe the change in quantity of T cells in patients with atopic dermatitis (AD) compared with healthy subjects. Other components of lymphocytes such as B cells are not examined as well as T cells. OBJECTIVE: We focus on immunophenotyping of B cells with their subsets (memory, naïve, switched, non-switched) and the expression of CD23 and CD200 markers in patients with AD with and without dupilumab therapy. We also evaluate the count of leukocytes and their subsets, T lymphocytes (CD4+, CD8+), natural killer (NK) cells, and T regulatory cells. METHODS: A total of 45 patients suffering from AD were examined: 32 patients without dupilumab treatment (10 men, 22 women, average age 35 years), 13 patients with dupilumab treatment (7 men, 6 women, average age 43.4 years), and 30 subjects as a control group (10 men, 20 women, average age 44.7 years). Immunophenotype was examined by flow cytometry in which monoclonal antibodies with fluorescent molecules were used. We compared the absolute and relative count of leukocytes and their subsets, T lymphocytes (CD4+ , CD8+), NK cells, T regulatory cells, absolute and relative count of B lymphocytes (memory, naïve, non-switched, switched, transient), and expression of CD23 and CD200 activation markers on B cells and on their subsets in patients with AD and control group. For statistical analysis we used nonparametric Kruskal-Wallis one-factor analysis of variance with post hoc by Dunn's test with Bonferroni modification of significance level. RESULTS: In patients with AD with and without dupilumab therapy we confirmed the significantly higher count of neutrophils, monocytes, and eosinophils; there was no difference in absolute count of B cells, NK cells and transitional B cells compared with control subjects. We confirmed higher expression of activation marker CD23 on total, memory, naïve, non-switched, and switched B lymphocytes and higher expression of CD200 on total B lymphocytes in both groups of patients with AD compared with controls. In patients without dupilumab therapy we confirmed significantly higher count of relative monocytes, relative eosinophils, and higher expression of CD200 on memory, naïve, and non-switched B lymphocytes compared with controls. In patients with dupilumab therapy we confirmed significantly higher expression of CD200 on switched B lymphocytes, higher count of relative CD4+ T lymphocytes, and lower count of absolute CD8+ T lymphocytes compared with controls. CONCLUSION: This pilot study shows higher expression of CD23 on B lymphocytes and on their subsets in patients with AD with and without dupilumab therapy. The higher expression of CD200 on switched B lymphocytes is confirmed only in patients with AD with dupilumab therapy.
- Publikační typ
- časopisecké články MeSH
BACKGROUND: The CD23 molecule has an effect on the regulation of IgE synthesis, either by stimulation or inhibition. It is not yet known whether the expression of CD23 on B lymphocytes is related to the level of allergen-specific IgE antibodies in patients with atopic dermatitis. AIM: The aim of this pilot study was to evaluate the association between the expression of CD23 molecule on B cells and on their subsets (memory, naive, switched, non-switched, and total B lymphocytes) and the level of specific IgE to molecular components of mites in atopic dermatitis patients (with and without dupilumab therapy). METHODS: Forty-five patients suffering from atopic dermatitis were included: 32 patients without dupilumab treatment (10 men, 22 women, average age 35 years), 13 patients with dupilumab treatment (7 men, 6 women, average age 43.4 years) and 30 subjects as a control group (10 men, 20 women, average age 44.7 years). The serum level of the specific IgE was measured using the components resolved diagnostic microarray-based specific IgE detection assay ALEX2 Allergy Xplorer. In all included patients, the expression of CD23 molecule on B lymphocytes was evaluated with flow cytometry using monoclonal antibodies. For the statistical analysis of the association between expression of CD23 molecule on B lymphocytes and the level of specific IgE to molecular components of mites, we used non-parametric Kruskal-Wallis one-factor analysis of variance with post-hoc by Dunn's test with Bonferroni modification and the Spearman's rank correlation coefficient; for coefficients higher than 0.41, we report R2 (%, percent of Variation Explained). RESULTS: The association between the expression of CD23 molecule on B cells and the level of specific IgE to molecular components of mites was confirmed only in patients with dupilumab therapy. In these patients, the highest association was confirmed between the level of specific IgE to Der p 20 and expression of CD23 on switched B lymphocytes (in 48.9%). In patients without dupilumab, the association between the level of specific IgE to molecular components of mites and the expression of CD23 on B cells and on their subsets is low. CONCLUSION: Further research is needed to fully understand the underlying mechanism of this phenomenon and its implications for the treatment of atopic dermatitis.
Our aim is to determine the number of leukocytes, T lymphocytes and B lymphocytes and the expression of activation markers CD200 and CD23 on B lymphocytes in atopic dermatitis (AD) patients (treated and not treated with dupilumab) during the pollen season. We examined 29 patients not treated with dupilumab, 24 patients treated with dupilumab and 40 healthy subjects as a control group. The count of T and B lymphocytes and their subsets were assessed by flow cytometry. The non-parametric Kruskal-Wallis one-factor analysis of variance with post hoc by Dunn's test with Bonferroni's modification was used for statistical processing. Although there was a significant improvement in skin findings in patients treated with dupilumab, the changes in immunological profile show a persistent altered immune response characterized by dysregulation and overactivation of B lymphocytes. Dupilumab therapy leads to normalization of relative T regulatory lymphocytes and total memory B lymphocytes and to decreased count of absolute CD8+ T lymphocytes. Why carry out this study?Studies investigating the immunological profile of atopic dermatitis (AD) patients during the pollen season are rare. There are no studies investigating the count of B lymphocytes (CD5+, CD22+ and CD73+ B lymphocytes) and the expression of activation markers CD23 and CD200 on B lymphocytes and on their subsets during pollen season in AD patients treated and non-treated with dupilumab therapy.What was learned from the study?In atopic dermatitis (AD) patients with and without dupilumab therapy, we confirmed the significantly higher count of absolute neutrophils, absolute monocytes, absolute eosinophils, absolute basophils, non-switched B lymphocytes, transitional B lymphocytes, CD23 memory, naive, non-switched, switched and total CD23 B lymphocytes, the relative count of CD200 memory and CD200 switched B lymphocytes.In dupilumab treated patients, we confirmed the significantly higher count of relative eosinophils, relative CD16+ eosinophils, relative CD200 non-switched B lymphocytes and lower count of absolute CD8+ T lymphocytes. Further studies should focus on investigating the effect of dupilumab on CD8+ T lymphocytes and their subpopulations.In patients without dupilumab therapy, we confirmed the significantly higher count of relative neutrophils, relative T regulatory lymphocytes and total memory B lymphocytes.The changes in the count of CD5+, CD22+ and CD73+ B lymphocytes were not observed during pollen season in both groups of AD patients.
- MeSH
- atopická dermatitida * farmakoterapie imunologie MeSH
- B-lymfocyty imunologie MeSH
- CD antigeny MeSH
- dospělí MeSH
- humanizované monoklonální protilátky * terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- pyl imunologie MeSH
- receptory IgE MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
European respiratory review, ISSN 0905-9180 vol. 11, review no. 81, September 2001
146-165 s. : il., tab. ; 28 cm
- MeSH
- bronchiální astma MeSH
- imunoglobulin E MeSH
- monoklonální protilátky MeSH
- receptory IgE antagonisté a inhibitory MeSH
- Publikační typ
- sborníky MeSH
- Konspekt
- Patologie. Klinická medicína
- NLK Obory
- pneumologie a ftizeologie
- alergologie a imunologie
Chronická kopř ivka (urtikarie CU) je definována jako přítomnost kopř ivky vyskytující se déle než šest týdnů . Etiologie onemocnění je různorodá, přičemž společ ným znakem většiny urtikarií je aktivace a degranulace žírných buněk a přičemž vyvolávací faktory mohou být jak neimunologického, tak imunologického charakteru. V patogenezi autoimunitní podskupiny je patogenní mechanismus spojován s přítomností protilátek IgG izotypu proti alfa podjednotce vysokoafinitního FcεRI receptoru nebo IgE. Diagnostika chronické kopřivky je obtížná a často založená pouze na klinických a anamnestických údajích. Do dnešního dne byla vyvinuta řada metod k detekci sérových autoprotilátek, je- jich nedostatkem je však značná různorodost v principu stanovení, a tudíž i vysoká metodická a mezilaboratorní variabilita. K nejužívanějším patří intradermální test za užití autologního séra (ASSST), který však nepatří mezi standardizovaná vyšetření. Laboratorní in vitro průkaz anti-FcεRI autoprotilátek je možno provádět funkč ními testy, jako je metoda uvolňování histaminu z basofilů periferní krve nebo imunoana- lytickými metodami jako western blot nebo enzymová imunoanalýza (ELISA). V této práci byla užita modifikace testu aktivace basofilů , kdy basofily zdravého byly stimulovány sérem pacientů s CU. Schopnost aktivoval basofily nealergického dárce vykazovala séra 5 z 11 vyšetřovaných pacientek a lze předpokládat, že aktivace basofilů byla mediována protilátkami proti FcεRI eventuálně anti-IgE protilátkami. Na rozdíl od metod založených na principu imunoanalýzy spočívá pozitivní přínos tohoto testu především v průkazu funkční aktivity séra vázané k FcεRI a odpovědné za aktivaci, resp. degranulaci basofilů a mohl by sloužit jako vhodná metoda pro identifikaci podskupiny pacientů s chronickou kopřivkou autoimunitního původu.
Chronic urticaria (CU) is defined as the presence of urticaria for at least 6 weeks. It is frequently caused by allergic reacti ons; however, there are many nonallergic causes. The majority of chronic urticaria cases have an unknown cause. The autoimmune subgroup is associat ed with the IgG anti-IgE receptor alpha subunit in 35–40% of patients and IgG anti-IgE in an additional 5–10%. These autoantibodies have be en shown to activate blood basophils and cutaneous mast cells in vitro with augmentation of basophil activation by complement and release o f C5a. This autoimmune subgroup can be identified by an autologous skin test or histamine release from human basophils or cutaneous mast ce lls or binding methods as immunoblot and ELISA. However, binding assays do not correlate with these functional assai. Activation of basophils or mast cells causing histamine release is quite specific for chronic urticaria and defines the autoimmune subgroup. To detect autoantibodies to the Fc ε RI in sera of CU patients by a modified serum-induced basophil activation test measured by flow cytometry. Sera of 11 CU patients wer e tested and serum of 5 of these sera upregulated CD63 expression on the surface of basophils. Chronic urticaria serum-induced CD63 expressi on assay seems to be a useful tool for identification of a subset of patiens with autoimmune CU.
